五、关于本次发行上市及"全流通"：(1)请按照《监管规则适用指引——境外发行上市类第2号》的要 求，说明本次发行上市方案，备案材料及招股说明书关于发行上市方案内容不一致的原因;(2)请说明本 次拟参与"全流通"股东所持股份是否存在被质押、冻结或其他权利瑕疵的情形。 六、请说明你公司前期在全国股转系统挂牌的详细情况及终止挂牌原因，前期进行A股上市辅导备案的 详细情况，是否继续推进A股上市计划及具体安排，是否存在对本次发行上市产生重大影响的情形。 二、关于股东情况：(1)请说明最近12个月内新增股东入股价格的合理性，该等入股价格之间存在差异 的原因，并就是否存在利益输送出具明确结论性意见;(2)请说明4名通过股转系统交易方式取得你公司股 票的股东其所持股份是否存在被质押、冻结或其他权利瑕疵的情形。 三、请说明你公司及下属公司经营范围包含"医学研究和试验发展;人体基因诊断与治疗技术开发;细胞技 术研发和应用;国家重点保护陆生野生动物人工繁育;驯养繁殖国家重点保护野生动物;畜禽养殖"的具体 情况，是否实际开展相关业务及具体运营情况，是否已取得必要的资质许可，经营范围及实际业务是否 涉及外商投资准入限制或禁止领域及相关 ...

智通财经APP获悉，1月5日，中国证监会公布《境外发行上市备案补充材料要求(2025年12月29日— 2026年1月4日)》。其中，中国证监会要求鼎泰药研补充说明关于股权变动等事项。据港交所2025年10 月31日披露，江苏鼎泰药物研究(集团)股份有限公司(简称：鼎泰药研)向港交所主板提交上市申请书， 花旗、海通国际为联席保荐人。 中国证监会请鼎泰药研补充说明以下事项，请律师核查并出具明确的法律意见： 一、关于股权变动：(1)请说明你公司历次增资及股权转让定价依据，是否实缴出资，是否存在未履行 出资义务、出资方式存在瑕疵的情形，并就你公司设立及历次股权变动是否合法合规出具明确结论性意 见;(2)请说明你公司设立香港鼎泰涉及的境外投资手续的办理进展，以及投资Xellar Ltd.相关ODI手续的 办理进展;(3)请按照《监管规则适用指引——境外发行上市类第2号》的要求，对你公司历史沿革中存在 的股份代持情形进行核查;(4)请按照《监管规则适用指引——境外发行上市类第2号》的要求，对你公司 外部顾问参与员工持股计划进行核查，并就是否存在利益输送、是否合法合规出具明确结论性意见。 二、关于股东情况：(1)请说明最近 ...

Group 1: Recent IPOs - Minglue Technology, a data intelligence application software company, successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 1.018 billion with a market capitalization of HKD 31.301 billion [1] - Seres, a new energy vehicle brand, completed its IPO on the Hong Kong Stock Exchange, raising around HKD 14.283 billion and achieving a market capitalization of HKD 247.6 billion [2] - Joyson Electronics, a provider of automotive technology solutions, successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 3.412 billion with a market capitalization of HKD 31.388 billion [3] - Wangshan Wangshui, a biopharmaceutical company, completed its IPO on the Hong Kong Stock Exchange, raising about HKD 0.587 billion and achieving a market capitalization of HKD 13.743 billion [4] - WeRide, an L4 autonomous driving technology company, successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 2.392 billion with a market capitalization of HKD 25.049 billion [5] Group 2: Companies Filing for IPO - Xinde Semiconductor, a semiconductor packaging and testing solutions provider, filed for an IPO on the Hong Kong Stock Exchange [6] - Haiguangxin, a provider of optical interconnect products, submitted an IPO application to the Hong Kong Stock Exchange, ranking 10th globally in professional optical module providers by revenue for 2024 [8] - Dingtai Pharmaceutical, a contract research organization, filed for an IPO on the Hong Kong Stock Exchange, offering integrated solutions for pharmaceutical companies and research institutions [9] - Haote Energy, an energy management solutions provider, submitted an IPO application to the Hong Kong Stock Exchange, focusing on data center energy management [10] - Guoxia Technology, a renewable energy solutions provider, filed for an IPO on the Hong Kong Stock Exchange, specializing in energy storage systems [11] - Tiantong Vision, an L4 solution provider, submitted an IPO application to the Hong Kong Stock Exchange, offering comprehensive intelligent driving solutions [12] - Lupeng Pharmaceutical, a platform-based pharmaceutical company, filed for an IPO on the Hong Kong Stock Exchange, focusing on high bioavailability oral drugs [13][14] - Libang Pharmaceutical, a biopharmaceutical company specializing in kidney disease, submitted an IPO application to the Hong Kong Stock Exchange [15] - FSTech, a provider of electric drive solutions, filed for an IPO on the Hong Kong Stock Exchange, ranking second in China's industrial control sector by revenue for 2024 [16] - Ketao Co., a smart parking space operator, refiled for an IPO on the Hong Kong Stock Exchange after a previous application expired [17] - Zhihui Interconnect, an AI company, submitted an IPO application to the Hong Kong Stock Exchange, focusing on urban traffic management solutions [18] - Taotao Vehicle, an electric mobility company, filed for an IPO on the Hong Kong Stock Exchange, ranking second globally in the electric low-speed vehicle industry by revenue for 2024 [19] - Nanhua Futures, a financial services provider, refiled for an IPO on the Hong Kong Stock Exchange after a previous application expired [20] Group 3: Companies Passing Hearings - Haiwei Electronics, a capacitor film manufacturer, passed the listing hearing on the Hong Kong Stock Exchange, ranking second in China by capacitor film sales volume for 2024 [21] Group 4: Companies Approved for Filing - Xidi Zhijia received approval for overseas issuance and "full circulation" of unlisted shares from the China Securities Regulatory Commission [22]

Core Viewpoint - Jiangsu Dingtai Pharmaceutical Research (Group) Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Citigroup and Haitong International acting as joint sponsors [1]. Company Overview - Established in 2008, Dingtai Pharmaceutical is a new type of Contract Research Organization (CRO) that provides integrated solutions based on disease biology for global pharmaceutical companies and research institutions. The company has transformed from a traditional CRO into a strategic R&D partner for clients [3]. - The company offers comprehensive non-clinical safety, efficacy, and drug metabolism and pharmacokinetics (DMPK) research, as well as integrated clinical trial services from proof of concept to pivotal trials, supporting clients throughout the entire lifecycle of drug development [3]. - Dingtai Pharmaceutical focuses on clinical value and has accumulated deep expertise and rich experience in cardiovascular metabolic diseases, central nervous system (CNS) diseases, ophthalmology, autoimmune diseases, and oncology [3]. Market Position - According to Frost & Sullivan, Dingtai Pharmaceutical is the largest CRO in China for non-clinical research in cardiovascular metabolic diseases based on projected revenue for 2024 [3]. - The company has built one of the most comprehensive non-human primate (NHP) disease model portfolios in China, ranking as the third-largest CRO in the field of efficacy research in China for 2024 [4]. Services and Capabilities - Dingtai Pharmaceutical's biomarker and translational medicine platform provides immunology, cellular, and molecular testing, supported by industry-leading sensitivity, robustness, and throughput characteristics in mass spectrometry bioanalysis [4]. - The company proactively monitors the progress of new therapies in key disease areas to anticipate industry trends and strategically expand its technical capabilities [4]. - Dingtai has extensive project experience in oligonucleotide therapies, monoclonal and bispecific antibodies, antibody-drug conjugates (ADC), and cell gene therapy (CGT) [4]. Client Base and Achievements - The company has established a loyal and diverse client base, including commercial-stage pharmaceutical companies, early-stage biotech firms, and well-known research institutions. Since its inception until October 24, 2025, Dingtai has provided non-clinical services to over 700 clients and clinical services to over 130 clients, assisting clients in obtaining over 200 approvals from the National Medical Products Administration (NMPA) and over 40 approvals from overseas regulatory agencies [5]. - Dingtai Pharmaceutical holds Good Laboratory Practice (GLP) certification and is recognized by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), enabling it to support clients in regulatory submissions in major global markets [5]. Financial Performance - The company's revenue for the years 2022, 2023, 2024, and the six months ending June 30, 2025, were approximately RMB 725 million, RMB 767 million, RMB 713 million, and RMB 377 million, respectively. The corresponding profits (losses) for the same periods were approximately RMB 143 million, -RMB 52 million, -RMB 252 million, and RMB 64 million [5][6].